Industry Trends

Industry experts touched on patient needs, rare diseases, and gender analysis among other topics in these written Q&As.

Applied Clinical Trials sat down on-site with many KOLs at some of industry's largest gatherings in 2023 including SCOPE, DIA, and DPHARM.

Throughout 2023, guests of the Applied Clinical Trials podcast spoke on a number of topics including clinical research in rare disease areas, data, and artificial intelligence.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

Pfizer's $43 billion deal to acquire Seagen will significantly bolster its current oncology portfolio with Seagen’s late-stage development programs and expertise in antibody-drug conjugates.

Deal includes Icosavax’s protein virus-like particle platform technology, which could significantly improve treatments to protect against severe infectious diseases.

BL-B01D1 is a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate currently being evaluated in the global, multi-center Phase I BL-B01D1-LUNG101 trial in patients with metastatic or unresectable non-small cell lung cancer.

How can we combat the sense of urgency our professional lives bring?

Decentralized clinical trials have the potential to expand the number of people who can benefit from clinical trials while accelerating therapies to more patients in need.

Education and equitable access are key to unlocking its full potential in the present and future.

Increased use of fentanyl underscores immediate need for better testing methods.

Findings suggests implementation could save time and money, but needs to be evaluated carefully.

The immense volume of available chemical compounds creates a significant challenge in the drug discovery process.

AI could present an innovative path forward in reshaping the landscape of global health strategies.

There is an expanding array of potential antibody-based treatment options, such as bispecific or multispecific antibodies, that show promise in addressing conditions such as cancer, engineered antibody fragments, or even antibody-drug conjugates.

Panel at recent Talk Health event at Le Méridien, in Philadelphia, PA, on September 11th, 2023, focused on what success looks like in audio from a publisher, vendor, and HCP perspectives.

Investigating more objectively measured 'structural' characteristics.

In this exclusive Q&A with Applied Clinical Trials, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

Raj Indupuri, CEO and co-founder of eClinical Solutions discusses the trends he is seeing with artificial intelligence in the clinical trials space.

Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.

In this Q&A, Jimmy Bechtel, MBA, VP of site engagement, Society for Clinical Research Sites discusses evolving challenges in the site landscape, what SCRS is doing to alleviate burden, as well as the organization’s upcoming event, the Global Site Solutions Summit in October 2023.

What does the future of digital health look like?

Cristina Varner, LUTCF, ARM, SVP/national life science and digital health & telemedicine practice leader at insurance brokerage Newfront explains the nuances of insuring clinical trials in today's growing digital health climate and the newer risks in areas such as cybersecurity that developers are facing.

Tufts CSDD study breaks down state of the talent pipeline from lens of senior leaders.

A point-of-view summary of a pharmaceutical presentation.

Study seeks to understand how different forms of data meet the needs of researchers.

Industry sees high increase in the use of QTLs.

Research shows there was no decline in non-COVID related study spending during height of pandemic.

Measuring different dimensions of diversity beforehand can lead to more thoughtful planning and execution.

Sunny Kumar, MD, partner at GSR Ventures speaks about reducing hospital readmissions for high-risk patients at the SCOPE 2023 conference in Orlando, FL.